A Case of Hepatitis B Virus Reactivation in a HBsAg-Negative and Anti-HBs-Positive Patient with Diffuse Large B-Cell Lymphoma after Rituximab plus CHOP Chemotherapy
Soonchunhyang Medical Science
; : 168-171, 2014.
Article
in Korean
| WPRIM (Western Pacific)
| ID: wpr-95062
Responsible library:
WPRO
ABSTRACT
The reactivation of hepatitis B virus (HBV) is well known complication among lymphoma patient related with chemotherapy. Rituximab is monoclonal antibody that targets B-lymphocytes for treatment of lymphoma and it increases reactivation of HBV. Although most of reactivation occurs in HBV carrier, it can also rarely occur when hepatitis B surface antigen (HBsAg) is negative. Furthermore it is less frequently reported in lymphoma patient when HBV serology shows HBsAg is negative and anti-HBs is positive. We report a case of HBV reactivation following 6 cycle of rituximab plus CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy for diffuse large B-cell lymphoma in HBsAg negative/anti-HBs positive 58-year-old male, with a review of the literature.
Full text:
Available
Database:
WPRIM (Western Pacific)
Main subject:
Vincristine
/
B-Lymphocytes
/
Doxorubicin
/
Hepatitis B virus
/
Lymphoma, B-Cell
/
Drug Therapy
/
Rituximab
/
Hepatitis B Surface Antigens
/
Lymphoma
Limits:
Humans
/
Male
Language:
Korean
Journal:
Soonchunhyang Medical Science
Year:
2014
Document type:
Article